DNLI - デナリ・セラピュ―ティクス （Denali Therapeutics Inc.） デナリ・セラピュ―ティクス

The share price of Denali Therapeutics Inc. (NASDAQ:DNLI) rose to $31.25 per share on Thursday from $31.01. While Denali Therapeutics Inc. has overperformed by 0.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DNLI fell by -40.15%, with highs and lows ranging from $56.80 to $20.24, […]

Denali Therapeutics press release (NASDAQ:DNLI): Q2 GAAP EPS of -$0.48 beats by $0.04.Revenue of $52.48M (+128.8% Y/Y) beats by $7.82M.

Berenberg has started Denali Therapeutics (DNLI) with a buy rating saying that the central nervous system-focused company has technology making it possible to get drugs into the brain.

Denali Therapeutics Inc (DNLI) shares closed today 11.8% higher than it did at the end of yesterday. The stock is currently down 52.1% year-to-date, down 71.0% over the past 12 months, and down 0.3% over the past five years. Today, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.2%. Trading Activity Shares traded as high as $24.37 and as low as $20.76 this week.Shares closed 70.0% below its 52-week high and 18.1% above its 52-week low.Trading volume this week was 36.1% higher than the 10-day average and 69.1% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 7.3% higher than its 5-day moving average, 1.0% higher than its 20-day moving average, and 16.4% lower than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 99.8% The company's stock price performance over the past 12 months lags the peer average by 167.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

PALM BEACH, Fla. , June 7, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still projected to continue to grow over the next years to come. Several factors that have contributed to the growth of the developed market in recent years including the increased Demand for Multiple Sclerosis drugs have helped to proliferate market growth. A report from Fortune Business Insight discussed the market and said that: "Based on disease segment type, the global CNS therapeutics market is classified as neurovascular diseases, neurodegenerative diseases, mental health, infectious diseases, and others. Neurodegenerative diseases dominated the market in 2020 owing to the growing sales for multiple sclerosis as well as Alzheimer''s disease drugs due to the rising prevalence of neurological disorders." In addition to growing addiction issues, the article continued: "Furthermore, rising cases of mental health disorders among the population owing to increased stress levels, anxiety, and unhealthy diet are also leading to a growing demand for CNS therapeutics.

Berenberg has started Denali Therapeutics (DNLI) with a buy rating saying that the central nervous system-focused company has technology making it possible to get drugs into the brain.

Denali Therapeutics Inc (DNLI) shares closed today 11.8% higher than it did at the end of yesterday. The stock is currently down 52.1% year-to-date, down 71.0% over the past 12 months, and down 0.3% over the past five years. Today, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.2%. Trading Activity Shares traded as high as $24.37 and as low as $20.76 this week.Shares closed 70.0% below its 52-week high and 18.1% above its 52-week low.Trading volume this week was 36.1% higher than the 10-day average and 69.1% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 7.3% higher than its 5-day moving average, 1.0% higher than its 20-day moving average, and 16.4% lower than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 99.8% The company's stock price performance over the past 12 months lags the peer average by 167.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

PALM BEACH, Fla. , June 7, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The global Central Nervous System (CNS) treatments and its market revenues had been steadily growing pre-pandemic and are still projected to continue to grow over the next years to come. Several factors that have contributed to the growth of the developed market in recent years including the increased Demand for Multiple Sclerosis drugs have helped to proliferate market growth. A report from Fortune Business Insight discussed the market and said that: "Based on disease segment type, the global CNS therapeutics market is classified as neurovascular diseases, neurodegenerative diseases, mental health, infectious diseases, and others. Neurodegenerative diseases dominated the market in 2020 owing to the growing sales for multiple sclerosis as well as Alzheimer''s disease drugs due to the rising prevalence of neurological disorders." In addition to growing addiction issues, the article continued: "Furthermore, rising cases of mental health disorders among the population owing to increased stress levels, anxiety, and unhealthy diet are also leading to a growing demand for CNS therapeutics.

Denali Therapeutics (DNLI) and partner Biogen (BIIB) said on Tuesday dosing had begun in the global Phase 2b study testing their drug, BIIB122 (DNL151), as compared to placebo in about…

BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson''s disease Phase 2b LUMA to enroll approximately 640 participants with early-stage Parkinson''s disease; most advanced clinical study of a LRRK2 inhibitor SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI ), and Biogen Inc. (NASDAQ: BIIB ) today announced that dosing has commenced in the global Phase 2b LUMA study to evaluate the efficacy and safety of BIIB122 (DNL151), as compared to placebo in approximately 640 participants with early-stage Parkinson''s disease. LUMA is a Phase 2b multi-center, randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of BIIB122 in people with early-stage Parkinson''s disease between the ages of 30 and 80. The primary endpoint of LUMA is Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson''s Disease Rating Scale (MDS-UPDRS) parts II and III combined score over the treatment period.

SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI ), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced upcoming presentations from the DNL310 (ETV:IDS) clinical development program to be given at the 18 th Annual WORLD Symposium ™, which will be held February 7-11, 2022, in San Diego, California, and virtually. DNL310 is an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system (CNS) and peripheral manifestations of MPS II (Hunter syndrome). An oral presentation will provide longer-term safety, biomarker (glycosaminoglycans and lysosomal lipids) and exploratory clinical data on Cohorts A and B from an ongoing Phase 1/2 clinical trial of DNL310 in MPS II. A poster presentation will provide details on a planned, potentially registrational Phase 2/3 clinical trial of DNL310 in MPS II.

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.

G Medical Innovations (GMVD) +20%. ChemoCentryx (CCXI) +12%. Denali Therapeutics Inc. (DNLI) -13%. Immix Biopharma (IMMX) -11%.

Denali Therapeutics (DNLI) is trading ~13.9% lower in the pre-market after announcing a clinical hold imposed by the FDA for the companys experimental therapy for Alzheimers

Denali Therapeutics Inc (DNLI) shares closed today at 1.7% above its 52 week low of $40.87, giving the company a market cap of $5B. The stock is currently down 6.8% year-to-date, down 48.1% over the past 12 months, and up 93.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 28.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -46.3% The company's stock price performance over the past 12 months lags the peer average by 257.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -171.0% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.